ADC Therapeutics SA Depreciation Expense
ADC Therapeutics SA (ADCT) reported Depreciation Expense of $1.02 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-15.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DepreciationExpense · last filed 2023-03-15
| Period end | Depreciation Expense 12 month |
|---|---|
| 2022-12-31 | $1.02M 20-F · filed 2023-03-15 |
| 2021-12-31 | $920.00K 20-F · filed 2023-03-15 |
| 2020-12-31 | $774.00K 20-F · filed 2023-03-15 |
| 2019-12-31 | $552.00K 20-F · filed 2022-03-17 |
| 2018-12-31 | $488.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |